

Supplementary Table 2: Patients characteristics and clinical data.

Characteristics	
Patients, n	24
Matched-pair, n	4
Metastasis, n	
Skin	21
Lung	1
Lymph node	2
Gender, n	Age (years \pm SD)
Female, 8	68 \pm 13
Male, 16	63 \pm 15
Therapy, n patients	
Pembrolizumab	14
Nivolumab	10
Clinical outcome, n (%)	
PD	11
PR	4
SD	6
CR	3

PD: progressive disease; PR: partial response; SD: stable disease; CR: complete response